Literature DB >> 15784640

Peritoneal dialysis patient survival: a comparison between a Swedish and a Korean centre.

Sung Hee Chung1, Olof Heimbürger, Bengt Lindholm, Hi Bahl Lee.   

Abstract

BACKGROUND: Dialysis patient mortality remains high, and this high mortality may be due to many factors. In peritoneal dialysis (PD) patients, old age, co-morbid diseases, malnutrition, low residual renal function (RRF) and a high peritoneal transport rate have been shown to influence survival, but the relative importance of these factors may differ between different patient populations. Besides, centre practice patterns may differ between centres and may influence patient survival. In addition, the literature suggests that dialysis patient survival may be better in Asian than in Caucasian patients.
METHODS: The influence of centre and patient characteristics on patient survival was investigated in 132 Korean and 106 Swedish incident PD patients, who underwent initial biochemical measurements and assessment of adequacy of dialysis, nutritional status, RRF and peritoneal transport characteristics.
RESULTS: At the start of PD, Korean patients had a higher prevalence of diabetes, peritoneal Kt/V(urea), peritoneal creatinine clearance and peritoneal fluid removal, and lower body mass index, RRF and dialysate to plasma creatinine concentration ratio (D/P Cr) compared with Swedish patients. Significantly more patients from Korea were placed on temporary haemodialysis before PD (100 out of 132) when compared with Swedish patients (21 out of 106). During the follow-up, there was a significantly higher rate of transfer to other units in Korea and a significantly higher rate of kidney transplantation in Sweden. On Kaplan-Meier analysis, overall patient survival did not differ and relative risk for death was also not different between the two centres even after adjustment for age, diabetes, cardiovascular disease, RRF and D/P Cr. On Cox proportional hazards multivariate analysis, age, diabetes, RRF and D/P Cr were found to be independent predictors of mortality in the combined cohort of patients. While age, diabetes and D/P Cr were independent predictors of mortality in Korean patients, age and RRF independently predicted mortality in Swedish patients.
CONCLUSION: Although there were significant differences in centre and patient characteristics, we were unable to confirm a survival advantage for Korean over Swedish PD patients. The results of this study suggest that the reported difference in survival between Asian and Caucasian dialysis patients may have been due, in part, to differences in centre and patient characteristics rather than to race as such. The genetic influence on patient characteristics remains, however, to be elucidated.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15784640     DOI: 10.1093/ndt/gfh772

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  14 in total

1.  Sevelamer use and incidence of peritonitis in peritoneal dialysis.

Authors:  Julia Kerschbaum; Paul König; Johann Hausdorfer; Gert Mayer; Michael Rudnicki
Journal:  Wien Klin Wochenschr       Date:  2011-03-28       Impact factor: 1.704

2.  Peritonitis is still an important factor for withdrawal from peritoneal dialysis therapy in the Tokai area of Japan.

Authors:  Masashi Mizuno; Yasuhiko Ito; Akio Tanaka; Yasuhiro Suzuki; Hideki Hiramatsu; Midoriko Watanabe; Yoshikazu Tsuruta; Teppei Matsuoka; Isao Ito; Hiroshi Tamai; Hirotake Kasuga; Hideaki Shimizu; Hisashi Kurata; Daijo Inaguma; Takeyuki Hiramatsu; Masanobu Horie; Tomohiko Naruse; Shoichi Maruyama; Enyu Imai; Yukio Yuzawa; Seiichi Matsuo
Journal:  Clin Exp Nephrol       Date:  2011-06-21       Impact factor: 2.801

Review 3.  Key factors for a high-quality peritoneal dialysis program--the role of the PD team and continuous quality improvement.

Authors:  Wei Fang; Zhaohui Ni; Jiaqi Qian
Journal:  Perit Dial Int       Date:  2014-06       Impact factor: 1.756

4.  Impact of continuous quality improvement initiatives on clinical outcomes in peritoneal dialysis.

Authors:  Yusheng Yu; Yan Zhou; Han Wang; Tingting Zhou; Qing Li; Taoyu Li; Yan Wu; Zhihong Liu
Journal:  Perit Dial Int       Date:  2014-06       Impact factor: 1.756

5.  Clinical outcomes of peritoneal dialysis patients transferred from hemodialysis: a matched case-control study.

Authors:  Li Zhang; Tao Cao; Zhibin Li; Qiong Wen; Jianxiong Lin; Xiaodan Zhang; Qunying Guo; Xiao Yang; Xueqing Yu; Haiping Mao
Journal:  Perit Dial Int       Date:  2012-11-01       Impact factor: 1.756

6.  Randomized controlled trial of icodextrin versus glucose containing peritoneal dialysis fluid.

Authors:  Aiwu Lin; Jiaqi Qian; Xiaomei Li; Xueqing Yu; Wenhu Liu; Yang Sun; Nan Chen; Changlin Mei
Journal:  Clin J Am Soc Nephrol       Date:  2009-10-01       Impact factor: 8.237

7.  Overestimation of the probability of death on peritoneal dialysis by the Kaplan-Meier method: advantages of a competing risks approach.

Authors:  Jean-Baptiste Beuscart; Dominique Pagniez; Eric Boulanger; Celia Lessore de Sainte Foy; Julia Salleron; Luc Frimat; Alain Duhamel
Journal:  BMC Nephrol       Date:  2012-05-30       Impact factor: 2.388

8.  Modelling competing risks in nephrology research: an example in peritoneal dialysis.

Authors:  Laetitia Teixeira; Anabela Rodrigues; Maria J Carvalho; António Cabrita; Denisa Mendonça
Journal:  BMC Nephrol       Date:  2013-05-24       Impact factor: 2.388

9.  Risk factors associated with peritoneal-dialysis-related peritonitis.

Authors:  Julia Kerschbaum; Paul König; Michael Rudnicki
Journal:  Int J Nephrol       Date:  2012-12-20

10.  Treatment with oral active vitamin D is associated with decreased risk of peritonitis and improved survival in patients on peritoneal dialysis.

Authors:  Julia Kerschbaum; Andreas Vychytil; Karl Lhotta; Friedrich C Prischl; Martin Wiesholzer; Veronika Machhold-Fabrizii; Gertrude Kopriva-Altfahrt; Christoph Schwarz; Peter Balcke; Rainer Oberbauer; Reinhard Kramar; Paul König; Michael Rudnicki
Journal:  PLoS One       Date:  2013-07-02       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.